Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report report published on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Trading Up 5.1 %

NASDAQ CPIX opened at $1.65 on Tuesday. The firm has a 50 day simple moving average of $1.89 and a 200-day simple moving average of $1.88. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.11 and a current ratio of 1.28. Cumberland Pharmaceuticals has a one year low of $1.43 and a one year high of $2.36. The firm has a market cap of $23.40 million, a price-to-earnings ratio of -3.75 and a beta of 0.16.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%. The firm had revenue of $9.35 million during the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its stake in Cumberland Pharmaceuticals by 6.3% in the first quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock worth $1,818,000 after acquiring an additional 38,100 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Cumberland Pharmaceuticals by 27.8% in the first quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock worth $529,000 after acquiring an additional 40,949 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Cumberland Pharmaceuticals in the third quarter worth approximately $142,000. Finally, Millennium Management LLC purchased a new position in Cumberland Pharmaceuticals in the fourth quarter worth approximately $46,000. Hedge funds and other institutional investors own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.